Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Overcoming the limits to widespread NGS implementation

Ola Landgren • 9 Dec 2017
ASH 2017
General

Next-generation sequencing (NGS) has been widely used in research for the past decade or more; however, its translation into the clinic has taken more time. Here, Ola Landgren, MD, PhD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the limits to widespread NGS implementation and how we can overcome them. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

More from Ola Landgren

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
3:51
Should HR-SMM be treated before progression to NDMM?
Ola Landgren • 20 Dec 2023
3:31
ADVANCE: Dara-KRd versus KRd in patients with NDMM
Ola Landgren • 20 Dec 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals